Guideline aims to recognize the risks, signs, and symptoms of acute HIV infection and to promote HIV testing in individuals presenting with flu-like symptoms or viral syndromes. It provides recommendations for diagnostic testing, treatment, and prevention services to improve patient health and reduc

0 views • 19 slides

This update highlights key points from the PMK No. 23/2022 on combating HIV, AIDS, and STIs. It covers terminologies, goals for eliminating HIV and AIDS by 2030, and strategies such as PrEP and PEP. The guidelines emphasize timely interventions like Post-Exposure Prophylaxis (PEP) and Pre-Exposure P

3 views • 38 slides

HIV and AIDS are closely related, with HIV being the virus that leads to AIDS. HIV weakens the immune system by attacking specific white blood cells, while AIDS is the advanced stage of HIV infection. Prevention is crucial as AIDS is a deadly, incurable disease. The transmission of HIV primarily occ

4 views • 14 slides

HIV, a member of the lentivirus subfamily of retroviruses, causes Acquired Immunodeficiency Syndrome (AIDS). HIV-1 and HIV-2 have distinct characteristics, with HIV-1 being global and HIV-2 primarily in West Africa. The virus encodes reverse transcriptase and has an envelope containing glycoproteins

1 views • 31 slides

HIV Post-Exposure Prophylaxis (PEP) is a crucial emergency medical response for individuals exposed to HIV, aiming to prevent infection. It involves a regimen of medications, tests, and counseling services initiated within 72 hours of exposure. HIV transmission occurs through body fluids like blood,

3 views • 27 slides

This content provides an overview of the relationship between TB and HIV, emphasizing the importance of testing HIV patients for latent TB infection and TB patients for HIV. It also outlines the guidelines for managing these co-infections, including diagnostic tests, treatment strategies, and patien

0 views • 17 slides

Exploring the various co-morbidities associated with HIV infection and factors contributing to their development. Discussions on disease clusters, impact of risk factors such as smoking and cardiovascular disease, and comorbidities in parents of PLWH compared to HIV-negative individuals. Insights in

0 views • 14 slides

PEPFAR is intensifying efforts on partner notification services for HIV prevention to address the global issue of undiagnosed HIV cases. The initiative aims to improve testing strategies, increase testing volumes, and enhance epidemic control. By reaching HIV testing targets and implementing efficie

0 views • 24 slides

This study led by Dr. Geoffrey Chipungu, an HIV/AIDS Specialist at UNICEF ESARO, explores the rates, trends, and factors associated with HIV viral load suppression (VLS) in children. The research reveals sub-optimal VLS rates in children compared to adults, highlighting the need for improved policie

5 views • 12 slides

HIV, Human Immunodeficiency Virus, attacks the immune system and can progress to AIDS if left untreated. Antiretroviral Therapy (ART) helps control HIV, allowing individuals to live healthy lives. The stages of HIV include Acute Infection, Chronic Infection, and the most severe stage, AIDS. Early de

0 views • 29 slides

This content provides detailed instructions for conducting HIV rapid tests using three different kits: Determine HIV-1/2 Rapid Test, Uni-Gold HIV-1/2 Rapid Test, and Bioline HIV-1/2 Rapid Test. The instructions include steps such as specimen collection, test device preparation, result interpretation

0 views • 5 slides

August 18, 2020, marked the 30th anniversary of the Ryan White CARE Act, a landmark legislation that established the Ryan White HIV/AIDS Program providing care and treatment services to individuals with HIV in the U.S. The Act has been amended several times to extend and revise its purpose, no longe

0 views • 21 slides

This training session focuses on the relationship between undernutrition and HIV, discussing how HIV/AIDS affects nutrition among People Living with HIV (PLHIV). It covers the benefits of good nutrition for PLHIV and provides recommendations for Nutrition Assessment, Counselling, and Support (NACS)

1 views • 27 slides

Human Immunodeficiency Virus (HIV) is a lentivirus that infects CD4 T lymphocytes, leading to Acquired Immunodeficiency Syndrome (AIDS). Cutaneous manifestations of HIV/AIDS vary depending on the stage of infection and CD4 T cell counts. Early signs include exanthem, oral hairy leukoplakia, candidia

0 views • 17 slides

In response to the HIV/AIDS pandemic, this study focuses on the effectiveness of Pre-Exposure Prophylaxis (PrEP) in reducing HIV transmission among African American men who have sex with men in Orangeburg, SC. The research aims to investigate the impact of PrEP compared to condom use, and the necess

0 views • 6 slides

Maria, a pregnant woman in Malawi, faces the challenge of an unexpected pregnancy and a positive HIV diagnosis. The scenario explores her concerns, midwifery diagnosis, preparation for HIV testing, disclosure of results, and maintaining confidentiality in antenatal care. It also delves into factors

0 views • 10 slides

12.7 million people worldwide inject drugs, with 1.7 million of them living with HIV. The prevalence of HIV among people who inject drugs is 13.1%, highlighting the need for comprehensive service provision including testing, needle programs, opioid therapy, and antiretroviral treatment. The data als

0 views • 4 slides

This presentation highlights the significance of Regenerating Islet-Derived Protein-3 (REG3) and Intestinal Fatty Acid Binding Protein (I-FABP) in microbial translocation, inflammation, and reservoir size in individuals living with HIV. REG3 and I-FABP serve as markers of gut epithelial damage and p

0 views • 7 slides

PrEP is a vital HIV prevention strategy; however, individuals with Acute HIV Infection (AHI) may inadvertently start PrEP due to the limitations of current screening methods. The ImPrEP project in Brazil, Mexico, and Peru aims to evaluate the feasibility of providing PrEP to MSM and transgender indi

0 views • 15 slides

Global declines in HIV testing and reductions in new initiators, coupled with disruptions in HIV services due to COVID-19, pose challenges for future healthcare. Short-term disturbances could lead to increased HIV-related mortality, emphasizing the need for program responses to mitigate adverse effe

0 views • 10 slides

HIV/AIDS presents complex medical and psychiatric challenges, including HIV-Associated Neurocognitive Disorders (HANDs), which impact patients, families, and caregivers. This presentation by Dr. Mary Ann Adler Cohen provides insights into the prevalence, impact, diagnosis, and treatment of HANDs, em

0 views • 56 slides

Study on long-acting lenacapavir in heavily treatment-experienced HIV individuals after 104 weeks revealed emergence of lenacapavir resistance-associated mutations. Lenacapavir, a potent HIV-1 capsid inhibitor, has shown activity against ARV-resistant strains. The CAPELLA study analyzed lenacapavir

0 views • 11 slides

This synthesis covers the importance of monitoring progress in HIV prevention through data cascades, the need for standardized frameworks, promoting effective HIV prevention programs in diverse social contexts, and the key pillars of combination HIV prevention strategies. It also outlines various HI

0 views • 40 slides

This session introduces basic epidemiological concepts, differentiates between HIV and AIDS, explains the HIV life cycle, and discusses how HIV is transmitted. Definitions of key terms like prevalence, incidence, mortality rate, and morbidity are provided. The session also highlights the differences

0 views • 30 slides

A mystery shopper study was conducted to assess the private sector's effectiveness in providing high-quality HIV self-testing services to adolescents and young people in Kenya. The study focused on pharmacies and private health facilities participating in an HIV self-testing demonstration project. M

0 views • 25 slides

The Prevention Scientific Committee and International Community Advisory Board emphasized key priorities for pregnant and breastfeeding mothers with HIV infection, such as optimizing current ARV strategies and implementing immune strategies for achieving zero transmission. The discussion also includ

0 views • 30 slides

In Module 3 of the HIV Rapid POC Training Program, you will learn how to handle delivering reactive (or positive) HIV test results to clients. It covers providing emotional support, discussing next steps in care, notifying and protecting partners, and reinforcing prevention messages. The module emph

1 views • 13 slides

The V3 region of gp120 plays a crucial role in HIV entry to CD4 T-cells by determining the coreceptor usage. Studies focus on the structural aspects of V3, its conservation, coreceptor binding, and antibody accessibility. The HIV envelope structure, including trimeric spikes with gp120 and gp41 glyc

0 views • 24 slides

Conduct a data-driven assessment of HIV prevention programme needs and barriers in Ghana based on the Ghana Road Map Baseline Survey components. Evaluate the country's preparedness in addressing HIV epidemic patterns and prevention response analysis. Identify key barriers hindering HIV prevention ef

0 views • 11 slides

HIV infection progresses in stages from acute infection with flu-like symptoms to a latency period of no symptoms, then advancing to AIDS where the immune system is significantly weakened, leading to opportunistic infections and HIV-related cancers. The virus targets CD4 cells, impacting the immune

0 views • 29 slides

Assessing virological success in primary HIV infection treatment at 24 weeks is pivotal for predicting outcomes and determining the relevance of this timeframe as an endpoint. This study evaluates a cohort of patients with primary HIV infection to identify predictive factors of virological failure a

0 views • 15 slides

Research led by Alida Bouris focuses on the feasibility and efficacy of a dyadic social support intervention to retain HIV-positive young Black men in HIV primary care. Supported by the National Institute of Mental Health, the project aims to enhance engagement in care and improve health outcomes th

0 views • 45 slides

In the study of therapeutic trials in HIV/HCV coinfection between 2014-2015, notable trials included ION-4 with LDV/SOF treatment for 12 weeks in HCV/HIV co-infection patients, showing high SVR rates in both treatment-naive and experienced patients. Another trial, Ally-2, involved Daclatasvir and So

0 views • 15 slides

The study focuses on initiating combination antiretroviral therapy for all HIV-infected individuals to preserve the CD4+ T cell population, restrict viral reservoir seeding, and minimize viral evolution. Rapid suppression of HIV viraemia in patients could lead to potential candidates for future cure

0 views • 12 slides

Study investigating the efficacy of dolutegravir (DTG) monotherapy in early HIV-1 infection showed non-inferiority compared to standard combination antiretroviral therapy (cART). The EARLY-SIMPLIFIED study involved 68 patients on DTG monotherapy and 33 on cART, with both groups achieving HIV RNA sup

0 views • 6 slides

HIV Project Summary Sheet and Figures include data on HIV prevalence by age and sex, viral load suppression among people living with HIV, achievement of the 90-90-90 goals, and more. The project is supported by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the CDC. Findings an

0 views • 7 slides

This presentation by Dr. Ricardo A. Franco focuses on the challenges faced in managing and treating patients with HIV/Hepatitis C virus coinfection. It discusses the burden of HCV mono-infection and HIV/HCV co-infection, the impact of HIV co-infection on survival in HCV-related cirrhosis, and the ro

0 views • 26 slides

The concept of Undetectable=Untransmittable (U=U) has reshaped how we approach HIV prevention, with evidence emphasizing viral load as a key factor in transmission risk. Landmark studies like the Partner Study and HPTN 052 have solidified the U=U message, showcasing significant reductions in HIV tra

0 views • 28 slides

The ART Clinic at SDA Hospital in Asamang, Kenya, is dedicated to providing care and treatment for HIV/AIDS patients. With a focus on HIV testing, counseling, psychological support, and providing ART drugs, the clinic aims to achieve the 90-90-90 target by 2030. Through key activities like the Know

0 views • 20 slides

GS-6207 is a novel long-acting HIV capsid inhibitor with promising antiviral activity and safety profile in people living with HIV. The study evaluates the efficacy of a single subcutaneous dose of GS-6207 in reducing plasma HIV-1 RNA levels over 10 days. Results show potential benefits for heavily

0 views • 13 slides